Clinical trials: Oncolytic Virus, active
Metastatic Melanoma
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.
- Trial name
- TUNINTIL-2 (NCT06961786)
- Testing
- TILT-123, TIL, Cyclophosphamide
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- TILT Biotherapeutics Ltd.
Melanoma
OH2 Injection in Melanoma
To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected salvage chemotherapy or best supportive care (BSC)…
- Trial name
- NCT05868707
- Testing
- OH2, Salvage chemotherapy or best supportive care
- Where
- 30 sites in China
- Volunteers
- 340 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Head and Neck Squamous Cell Carcinoma, Oncolytic Virus
H101 Plus TACE for r/m HNSCC
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
- Trial name
- NCT07398664
- Testing
- H101, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Advanced Solid Tumor
Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors
To evaluate the safety and tolerability of combined administration of VSV injection solutions carrying different targets via multiple routes for treating advanced malignant solid tumors.
- Trial name
- NCT07656116
- Testing
- VSV injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recurrent High-grade Glioma
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12…
- Trial name
- NCT06763965
- Testing
- BioTTT001 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Advanced Solid Tumors
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid…
- Trial name
- NCT05914376
- Testing
- Recombinant human IL-21-expressing oncolytic vaccinia virus injection
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Hangzhou Converd Co., Ltd.
CRC, Liver Metastasis Colon Cancer
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
This prospective study aims to investigate the efficacy and safety of peritumoral injection of the oncolytic virus H101 in combination with stereotactic body radiotherapy (SBRT), PD-1 monoclonal antibody, chemotherapy, and…
- Trial name
- VVSHIP (NCT07381309)
- Testing
- SBRT, PD-1 Antibody, H101
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Jun Huang
Glioma
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
The goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.
- Trial name
- NCT07076498
- Testing
- M032
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
High-grade Glioma
A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
A single-arm clinical study on the efficacy and safety of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in the treatment of recurrent high-grade glioma
- Trial name
- NCT07472790
- Testing
- Novel oncolytic virus Ad-TD-nsIL12（BioTTT001）
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Treatment-Refractory Solid Tumors
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of…
- Trial name
- NCT07190833
- Testing
- OTS-412, Hydroxyurea (HU), Atezolizumab
- Where
- 2 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- Bionoxx Inc.
Solid Tumor, Gastrointestinal Cancer
OH2 Oncolytic Viral Therapy in Solid Tumors
This phase I/II study evaluates the safety and efficacy of OH2 as single agent or in combination with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal cancers, head and neck cancers, soft…
- Trial name
- NCT03866525
- Testing
- OH2 injection, with or without irinotecan or HX008
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Gastric Cancer, Metastatic
A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.
- Trial name
- NCT06283121
- Testing
- BioTTT001 intraperitoneal infusion, SOX regimen, toripalimab
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Rare Malignant Neoplasm, Advanced Solid Tumors
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
The goal of this Phase I/II observational and interventional platform study is to evaluate the safety and efficacy of multiple types of innovative anti-tumor drugs and new technologies in patients with rare solid tumors.
- Conditions
- Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors
- Trial name
- NCT07307053
- Testing
- BL-B01D1, VSV injection, CVL006
- Volunteers
- 600 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma, Adult
PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with programmed cell death protein antibody (anti-PD1) therapeutic regimen will be evaluated in patients with refractory primary…
- Trial name
- NCT07018518
- Testing
- PIN +anti-PD1
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chinese PLA General Hospital
Breast Cancer Metastatic
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human…
- Trial name
- NCT04215146
- Testing
- Paclitaxel, Pelareorep, Avelumab
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- Oncolytics Biotech
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single…
- Trial name
- NCT04735978
- Testing
- RP3, Nivolumab
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 123 people
- Sponsor
- Replimune, Inc.
Neuroendocrine Carcinoma, Neuroendocrine Tumors
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2.
- Trial name
- NCT06889493
- Testing
- Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Peter Hosein, MD
Advanced Malignant Solid Tumor
YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases
The preclinical pharmacological mechanism of YH02 injection is well established. By constructing a vector expressing MMP13, introducing a human S promoter, and genetically modifying the capsid protein, the virus's permeability…
- Trial name
- YH02 (NCT07697937)
- Testing
- YH-02
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin First Central Hospital